| - New Drug Application for Arzerra submitted to Japanese regulatory authorities COPENHAGEN, Denmark, April 27, 2012 (GLOBE NEWSWIRE) -- GlaxoSmithKline (GSK) and Genmab A/S (Copenhagen:GEN) announced today the submission of a New Drug Application (NDA) to the Japanese Ministry of Health, Labor and Welfare (MHLW) for Arzerra(R) (ofatumumab) for the treatment of chronic lymphocytic leukemia (CLL). "This marks another important achievement in our collaboration with GSK for Arzerra," said Jan...continued GNMSF GNMSY |
Friday, April 27, 2012
New Drug Application for Arzerra Submitted in Japan
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment